Phase 1
๐ Investigational Drug / Biologic
NCT07439887
Phase 1/2 Open-Label Dose-Escalation Study to Evaluate Safety of a Single Intravitreal Injection of RTx-021 in Patients With Stargardt Disease
๐ RayTx Clinical Site โ Bakersfield, California
View Study & Screener โ